Difference between revisions of "Tarlatamab (Imdelltra)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the NCI Drug Dictionary: A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against...") |
m (Jwarner moved page Tarlatamab (AMG-757) to Tarlatamab (Imdelltra): FDA approval) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
From the NCI Drug Dictionary: A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. | From the NCI Drug Dictionary: A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Small cell lung cancer]] | |
| − | + | ||
| + | ==History of changes in FDA indication== | ||
| + | *2024-05-16: Granted accelerated approval for extensive stage [[small cell lung cancer]] (ES-SCLC) with disease progression on or after platinum-based chemotherapy. ''(Based on DeLLphi-301)'' | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' AMG-757 | ||
| + | *'''Brand name:''' Imdelltra | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 11: | Line 17: | ||
[[Category:Anti-DLL3-CD3 bispecific antibodies]] | [[Category:Anti-DLL3-CD3 bispecific antibodies]] | ||
| − | [[Category:Small cell lung cancer medications | + | [[Category:Small cell lung cancer medications]] |
| − | [[Category: | + | [[Category:FDA approved in 2024]] |
Latest revision as of 18:51, 17 May 2024
Mechanism of action
From the NCI Drug Dictionary: A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 2024-05-16: Granted accelerated approval for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. (Based on DeLLphi-301)
Also known as
- Code name: AMG-757
- Brand name: Imdelltra